Michael Shankman - Lexaria Bioscience Chief Officer
| LEXX Stock | USD 2.08 0.01 0.48% |
Executive
Michael Shankman is Chief Officer of Lexaria Bioscience Corp
| Address | 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 |
| Phone | 250 765 6424 |
| Web | https://lexariabioscience.com |
Michael Shankman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Shankman against Lexaria Bioscience stock is an integral part of due diligence when investing in Lexaria Bioscience. Michael Shankman insider activity provides valuable insight into whether Lexaria Bioscience is net buyers or sellers over its current business cycle. Note, Lexaria Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lexaria Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Shankman over three weeks ago Insider Trading |
Lexaria Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7066) %, meaning that it created substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.14 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.52). At this time, Lexaria Bioscience's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2024, whereas Intangible Assets are likely to drop slightly above 295.9 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Michael Howell | Zura Bio Limited | 47 | |
| MD FFPM | Immix Biopharma | 64 | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
| Tom Mullen | LMF Acquisition Opportunities | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| David Marks | Immix Biopharma | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Tim Varacek | LMF Acquisition Opportunities | N/A | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Daniel MBA | Biodexa Pharmaceticals | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Verender Badial | Zura Bio Limited | 52 | |
| Steve Ellul | Biodexa Pharmaceticals | N/A | |
Management Performance
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.38 |
Lexaria Bioscience Corp Leadership Team
Elected by the shareholders, the Lexaria Bioscience's board of directors comprises two types of representatives: Lexaria Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexaria. The board's role is to monitor Lexaria Bioscience's management team and ensure that shareholders' interests are well served. Lexaria Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexaria Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Bunka, Chairman CEO | ||
| Vanessa Carle, Head Legal | ||
| Philip Ainslie, Advisor Consultant | ||
| Nelson CPA, Chief Officer | ||
| CPA CMA, Chief Officer | ||
| Richard Christopher, Chief Officer | ||
| John MSc, President Director | ||
| Michael CPA, Chief Officer | ||
| Michael Shankman, Chief Officer | ||
| Kristin Hamilton, Director Operations | ||
| Mike Shankman, Chief Officer |
Lexaria Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexaria Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (20.75) % | ||||
| Current Valuation | 29.88 M | ||||
| Shares Outstanding | 17.45 M | ||||
| Shares Owned By Insiders | 7.00 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 342.37 K | ||||
| Price To Book | 4.52 X | ||||
| Price To Sales | 88.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.